Acumen Pharmaceuticals, Inc. (ABOS)
| Market Cap | 120.77M -6.0% |
| Revenue (ttm) | n/a |
| Net Income | -105.04M |
| EPS | -1.64 |
| Shares Out | 72.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 602,707 |
| Open | 1.710 |
| Previous Close | 1.745 |
| Day's Range | 1.660 - 1.755 |
| 52-Week Range | 1.500 - 3.600 |
| Beta | 0.33 |
| Analysts | Strong Buy |
| Price Target | 7.60 (+355.09%) |
| Est. Earnings | Nov 11, 2026 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $7.6, which is an increase of 355.09% from the latest price.
News
Acumen Pharmaceuticals Transcript: Investor Day 2026
A novel anti-Aβ oligomer antibody is advancing through a pivotal phase II trial in early Alzheimer's, aiming to differentiate on both efficacy and safety. Enhanced brain delivery candidates show promising preclinical results, with IND filing targeted for 2027. Market growth is driven by improved diagnostics and a large, underserved patient population.
Acumen Pharmaceuticals Slides: FY 2026
Acumen Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 16, 2026.
Citi ups Acumen target, opens ‘upside 90-day catalyst watch’
Citi analyst Geoff Meacham raised the firm’s price target on Acumen (ABOS) to $5 from $4 and keeps a Buy rating on the shares. Citi also added an “upside 90-day…
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
The Alzheimer's market is rapidly expanding, with a novel phase II therapy targeting toxic A-beta oligomers expected to report pivotal data in late 2026. Robust trial design, strong KOL support, and an innovative brain delivery platform position the pipeline for future growth.
Acumen Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Sabirnetug, a highly selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027, with two candidates in development. ALTITUDE results will validate the oligomer hypothesis and guide future pipeline decisions.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloi...
Acumen Pharmaceuticals Earnings Call Transcript: Q2 2026
Sabirnetug's phase II ALTITUDE-AD trial remains on track for late 2026 top-line results, with robust clinical and biomarker endpoints and strong financial runway into 2027. Two new EBD candidates advance preclinical development, and digital and fluid biomarker strategies are expanding.
Acumen Pharmaceuticals Earnings release: Q2 2026
Acumen Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Quarterly report: Q2 2026
Acumen Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...
Acumen Pharmaceuticals Slides: Corporate presentation
Acumen Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...
Acumen presents new findings at AAIC conference
Acumen (ABOS) announced new findings presented at the Alzheimer’s Association International Conference 2026 in London. Following collaboration with JCR Pharmaceuticals on EBD candidate development, st...
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyl...
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyl...
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...
Acumen nominates two development candidates in EBD program
Acumen (ABOS) announced the nomination of two development candidates in its Enhanced Brain Delivery, or EBD, program as treatments for AD. Building on preclinical data from both in vitro and…
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid olig...
Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Sabirnetug, a monoclonal antibody targeting Aβ oligomers, is advancing through phase II trials with promising biomarker and safety data. Enhanced brain delivery programs and strategic partnerships aim to further improve efficacy, while the field anticipates combination therapies for Alzheimer's.
Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026
Phase II ALTITUDE-ad trial for sabirnetug is on track, with top-line results expected late 2026 and strong physician interest in its differentiated approach. Cash position supports operations into early 2027, and the EBD program is advancing with significant preclinical progress.
Acumen Pharmaceuticals Earnings release: Q1 2026
Acumen Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Quarterly report: Q1 2026
Acumen Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that t...
Acumen Pharmaceuticals Slides: Corporate presentation
Acumen Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.